Skip to content
Subscriber Only

Gilead Wins FDA Approval for Blockbuster Hepatitis C Pill

Gilead Sciences Inc. won U.S. approval for a hepatitis C pill that may generate more than $6 billion in annual sales as it leads a market for drugs that work faster to combat the disease with fewer side effects.

The $84,000 treatment is the first all-oral combination for some hepatitis C patients that helps avoid the flu-like symptoms caused by interferon injections, part of the current standard of treatment. The Food and Drug Administration said today it cleared sofosbuvir, which Gilead will call Sovaldi, for use with other drugs depending on the type of illness.